<DOC>
	<DOCNO>NCT02902731</DOCNO>
	<brief_summary>SYNOPSIS The giant cell arteritis ( GCA ) frequent vasculitis people 50 year . Despite recent progress physiopathogenic , corticosteroid remain standard treatment decade good initial clinical efficacy high relapse rate ( nearly 40 % 6,5 month ) decay . This sensible population particularly exposed side effect corticosteroid , lead think saving strategy . But association immunosuppressive therapy and/or anti- TNFα demonstrate benefit term efficiency long-term tolerance cumulative dose prednisone . The responsibility proinflammatory cytokine TNFα , IL- 6 IL-1 study pathogenesis GCA temporal artery wall mouse model . The primary pathogenic role IL- 1 base increase serum nuclear protein mRNA . The study temporal artery biopsy show increased local production IL- 1β mRNA , IL- 6 TGFβ ( indicative macrophage activation ) INFɣ IL 2 ( indicative T lymphocyte activation ) . Recently , Ly et al ( Ly KH JBS 2014 ) report efficacy anakinra , recombinant molecule IL- 1RA specifically block IL- 1 α/β , three case GCA refractory conventional treatment . Here investigator propose randomize , multicenter , control , double-blind study anakinra placebo addition corticosteroid treatment GCA . This study include 70 patient randomize equally arm : reference treatment ( prednisone plus placebo ) experimental treatment ( prednisone + anakinra ) . Treatment prednisone identical two arm , namely dose 0.7 mg/kg/day orally day 1 , follow progressive decrease dose pattern depend weight . In experimental arm , dose anakinra one usually use , ie 100 mg/day subcutaneous injection day 1 end week 16 ( S16 ) . In reference arm treatment , placebo anakinra associate corticosteroid packaging , duration respect double-blind . Investigators thus hypothesize addition anakinra corticosteroid compare placebo add latter , show significant decrease GAC relapse rate . Indeed , challenge corticosteroid therapy disease much problem initial effectiveness , adverse event related relapse steroid dependence .</brief_summary>
	<brief_title>Giant Cell Arteritis Anakinra Trial</brief_title>
	<detailed_description>Side assumption investigator make patient receive anakinra add-on therapy : time complete remission rate respectively shorter high , few relapse decrease total consumption prednisone 12- month follow-up . This control study first assess inhibition IL- 1 pathway GCA anakinra add-on therapy corticosteroid patient newly diagnose relapse . The purpose work support follow proof concept addition anakinra corticosteroid therapy treatment GCA : potential synergy association intrinsic therapeutic action anakinra patient newly diagnose , without loss opportunity patient benefit reference treatment . The originality study demonstrate steroid-sparing effect target interleukin -1 , per se therapeutic nosologic innovation disease . Finally , ancillary biological study clarify mode action anti-cytokine therapy identify marker response biotherapy .</detailed_description>
	<mesh_term>Arteritis</mesh_term>
	<mesh_term>Giant Cell Arteritis</mesh_term>
	<mesh_term>Polymyalgia Rheumatica</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Minimum Age : 51 Years Maximum Age : Gender : Both Accepts Healthy Volunteers ? : No Criteria : ( Giant cell arteritis = GCA ) Age ≥ 50 year Patient temporal arteritis giant cell match 3 5 criterion American College Rheumatology ( ACR ) : Given temporal artery biopsy compatible diagnosis GCA ( necrotizing arteritis , giant cell granulomatous inflammatory infiltrate , usually localize intimamedia junction , make lymphocyte , macrophage multinucleated giant cell ; minimum detection chronic inflammatory infiltrate fact lymphocytes neutrophil eosinophil without giant cell ) . Either abdominal thoracic aortitis diagnose : Angio CT : circumferential thicken aortic wall 3 mm , absence adjacent plaque active infection . MR angiography : wall thicken aortic wall hyperintense T1 weight T2 weight enhancement gadolinium injection . PET scanner : increased uptake FDG aorta branch typical GCA may atheroma . The PET scanner probably sensitive technique specific enough retain diagnosis GCA . We therefore consider PET CT diagnostic method secondary aortite GCA simultaneously exam fix aortic ( thoracic abdominal ) blood large caliber ( artery ( ) axillary ( ) , subclavian ( ) / carotid ( ) FDG . Newly diagnose disease corticosteroid start 14 day , initial dose less equal to1 mg / Kg GCA recurrence continuous therapy corticosteroid ( include hydroprednisone ) / immunosuppression stop least 6 month . At time recurrence , least 3 5 ACR criterion diagnosis GCA must present . Furthermore : BAT ( Biopsy temporal artery ) positive time initial diagnosis , necessary make new . BAT negative , patient include completion new BAT positive aortite , evidence angioCT MR angiography PET scanner . For men woman childbearing age , effective contraception must use patient partner duration treatment anakinra ( placebo ) 3 month treatment . Also , breastfeed allow 3 month stop anakinra . Women consider risk pregnancy define menopause least year surgically sterile ( tubal ligation , bilateral oophorectomy hysterectomy ) Patient wo give write consent Patient affiliate social security Subjects check one criterion noninclusion may eligible participate research . These criterion may include : 1. pathology , habitus patient characteristic Pregnancy , breastfeed woman woman childbearing potential use contraception dementia syndrome Patient observe Patients live 150 km investigation center ethyl drug intoxication history require hospitalization previous year Patient monitoring / treat another autoimmune disease know inflammatory Hypersensitivity anakinra excipients ( Sodium citrate ( E331 ) , sodium chloride , disodium edetate ( E385 ) , polysorbate 80 ( E433 ) , sodium hydroxide ( E524 ) , water injection , substrates origin : Escherichia coli protein ) Person judicial protection , guardianship Person deprive liberty Person beneficiary social security system 2 . Other therapeutic Patient already start ( stop less 6 month ) protocol frame ACG another disease , treatment anti TNFalpha , methotrexate , cyclosporine , cyclophosphamide , dapsone bolus corticosteroid . Patients longterm glucocorticoid another condition Early treatment CAG disease dose &gt; 1 mg / kg whatever duration Immunization live vaccine / mitigate 8 week 3 . Infectious disease Chronic viral hepatitis ( acute ) B C HIV Infection Persistent infection severe infection require hospitalization treatment IV antibiotic 30 day prior inclusion Infection require oral antibiotic treatment precede 14 day inclusion History active tuberculosis , histoplasmosis listeriosis latent TB Signs ( base history untreated contagion , opacity great 1 cm diameter chest xray , vitro test ( Quantiferon Gold TSpot TB ) positive . A history tuberculosis disease latent TB whose treatment complete properly conduct exclusion criterion , whatever result Quantiferon TSpot TB . 4 . Unstable disease Uncontrolled diabetes history recurrent infection unstable ischemic heart Heart failure ≥ stage III / IV NYHA Stroke recent ( &lt; 6 month ) Or severe disease result opinion investigator , risk patient due participation study . 5 . A vascular risk , metabolic , infectious , neoplastic renal follow : • Patient high cardiovascular risk : heart disease vascular history proven , type 2 diabetes high cardiovascular risk * , vascular risk &gt; 20 % 10 year ( Framingham equation ) Dyslipidemia • severe uncontrolled lipidlowering therapy Active Liver disease liver failure Neutropenia ( &lt; 1500 / mm3 ) time introduction Kineret / Placebo ; patient initial neutropenia may include study corrects Cortancyl® , experimental treatment ( AnakinraKineret / PLACEBO ) may commence within 15 day prednisone . Neoplasia 5 year except carcinoma situ cervix skin cancer ( exclude melanoma ) complete excision whose boundary pass safe area . • Severe renal impairment ( clearance &lt; 30mL / min ) * The high cardiovascular risk patient diabetes define : A kidney disorder ( proteinuria &gt; 300mg / 24h creatinine clearance &lt; 60mL / min accord Cockroft ) Or least two follow risk factor : Men 50 year , 60 year old woman History premature coronary disease : myocardial infarction sudden death father relative first degree male age 55 age 65 female Current quit smoke less 3 year High blood pressure treat HDL cholesterol &lt; 0.40 g / L regardless sex Microalbuminuria ( &gt; 30 mg / 24h ) NB : The moderate renal impairment ( clearance ≥ 30 mL / min &lt; 50 mL / min ) criterion noninclusion , appropriate injection KINERET ( anakinra ) provide daily make every two day .</criteria>
	<gender>All</gender>
	<minimum_age>51 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>